Insulet (NASDAQ:PODD) Upgraded at StockNews.com

StockNews.com upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a research report sent to investors on Monday morning.

Other research analysts have also issued research reports about the company. Wells Fargo & Company lifted their target price on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insulet Stock Up 1.5 %

NASDAQ PODD opened at $270.64 on Monday. The stock has a market cap of $18.98 billion, a PE ratio of 46.74, a P/E/G ratio of 3.62 and a beta of 1.23. The business has a 50 day moving average price of $273.69 and a two-hundred day moving average price of $249.20. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, sell-side analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. boosted its position in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. Raymond James & Associates boosted its position in shares of Insulet by 3.8% during the third quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock valued at $8,718,000 after purchasing an additional 1,367 shares in the last quarter. Private Advisor Group LLC raised its holdings in Insulet by 131.8% in the third quarter. Private Advisor Group LLC now owns 7,387 shares of the medical instruments supplier’s stock worth $1,719,000 after purchasing an additional 4,200 shares in the last quarter. International Assets Investment Management LLC lifted its position in Insulet by 23,175.0% during the third quarter. International Assets Investment Management LLC now owns 37,240 shares of the medical instruments supplier’s stock valued at $8,668,000 after buying an additional 37,080 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Insulet by 11.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,810 shares of the medical instruments supplier’s stock valued at $3,900,000 after buying an additional 1,712 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.